FISH-BASED INVESTIGATION OF CDKN2A AND IFNA14 IN GLIOBLASTOMA

Abstract AIMS Glioblastoma (GBM) tumours have a dismal prognosis despite aggressive anticancer therapy. Deletion of CDKN2A is among the most common genetic changes in GBM (~50%) and has been strongly associated with worse prognosis. Next generation DNA sequencing had shown that deletion IFNA genes (located proximal to CDKN2A) also major event (~25%). Clinical Identification vivo state these two might facilitate improved individualized therapeutics. METHOD Glioma tissue microarray consisting 45 samples was used assess co-deletion IFNA14 simultaneously, using novel three-color fluorescence situ hybridization (FISH) probe. We examined correlation between p16INK4a protein expression detected immunohistochemistry (IHC). RESULTS FISH analysis showed 44% primary GBMs harboured homozygous deletions both CDKN2a INFA14. By contrast, all grade II III gliomas, either wild-type or amplified All (n=11) were negative for staining, while 20 cores positive did not harbour deletion. Survival curves suggested CDKN2A/INFA14 shorter survival time. CONCLUSIONS Our FISH/IHC analyses indicate strong III/II glioma, suggesting amplification act as gatekeeper reduce incidence IV. data highlight high frequency together impact on